Primary Objectives:
* Evaluate the safety and feasibility of CDT (disulfiram + copper gluconate) during RT in patients undergoing radiotherapy within the thorax.
* Evaluate the progression free survival (PFS) time.
Secondary Objectives:
* Monitor all treatment-related adverse events from CDT during RT.
* Assess local control (LC) at 6 months.
Exploratory Objectives:
* Evaluate cuproptosis-related gene expression and biomarkers of copper metabolism in the baseline biopsy tissues and associate with treatment response. We aim to identify cuproptosis gene signatures (e.g., FDX1, LIAS, DLAT, PDHA1, MT1E, MT1X) as predictive biomarkers of therapeutic response.
* Evaluate the potential for continued CDT during adjuvant immunotherapy
